💸 The Tape

Read this sentence carefully and ask yourself if it sounds like something that should be coming out of an American state legislature in 2026:

A state lawmaker just asked his attorney general to prosecute medical cannabis businesses for serving patients with terminal illnesses, ALS, Parkinson's disease, and sickle cell anemia.

That's not a hypothetical. That's what happened in Kentucky on Tuesday.

House Majority Whip Jason Nemes (R-Louisville) stood before the Interim Joint Committee on Judiciary and called Governor Andy Beshear's executive order expanding qualifying conditions for medical marijuana an "unlawful expansion" — then went further, asking Attorney General Russell Coleman (R) to ensure state agencies "not cooperate" with the order and that any licensee participating "should be prosecuted" and "lose their license."

"This is not the way forward," Nemes said.

Let's be very clear about what "this" is. "This" is allowing a patient with ALS — a disease that progressively destroys the nerve cells controlling voluntary muscle movement until the patient can no longer speak, eat, move, or breathe — to access medical cannabis without waiting until their condition meets some arbitrary threshold of severity. "This" is letting a doctor recommend cannabis to someone with sickle cell anemia, a hereditary blood disorder that causes excruciating pain crises requiring frequent hospitalization. "This" is providing an alternative to opioids for people with terminal illness who are, by definition, dying.

And a sitting Republican legislator wants the people who help those patients prosecuted.

What the Governor Actually Did

Beshear's June 2 executive order added 15 conditions to the state's qualifying list — including terminal illness, ALS, Parkinson's, HIV/AIDS, Huntington's disease, muscular dystrophy, Crohn's disease, ulcerative colitis, severe arthritis, fibromyalgia, and glaucoma. He framed the action as a clarification, not an expansion, arguing that since the existing law already covers chronic pain and nausea, conditions that inherently produce those symptoms should logically be covered.

A patient with sickle cell anemia experiences pain. Pain is already a qualifying condition. Therefore, the governor reasoned, sickle cell anemia patients are already eligible — they just don't know it because the law lacks specificity. The executive order directs the Office of Medical Cannabis to issue an emergency regulation making that explicit.

Beshear's spokesperson Scottie Ellis put it plainly: "It's ultimately up to an individual's doctor or APRN to make the decision of whether a person has a qualifying condition. The Governor's action helps doctors and nurses better understand the law."

The Absurdity

Nemes's response isn't just aggressive — it's logically incoherent when placed against the current landscape of cannabis policy in America.

Kentucky's medical program launched in January 2025 after Beshear signed legalization into law in 2023. The state has licensed 32 medical cannabis businesses, authorized approximately 500 medical professionals to recommend cannabis, and enrolled nearly 24,000 patients. During the November 2024 election, more than 100 cities and counties voted to allow medical cannabis businesses in their jurisdictions. The program exists. It's operating. Patients are being served.

Meanwhile, at the federal level, President Trump's DOJ rescheduled state-licensed medical cannabis to Schedule III just weeks ago. The DEA is actively registering medical cannabis operations. Trulieve is trading on the NYSE. The federal government has formally acknowledged that medical marijuana has accepted medical use.

And in this environment, a Kentucky legislator wants to prosecute dispensary operators for serving patients with Parkinson's disease.

Nemes warned that the legislature wants "the tightest medical marijuana program in the country." But there's a difference between a tight program and a cruel one. When your qualifying conditions are so narrow that a patient with a terminal diagnosis can't access cannabis until they meet some legislatively defined threshold of suffering, you haven't built a tight program — you've built a bureaucratic obstacle course designed to deny care to people who need it most.

The Kentucky Market: Who's at Risk

The operators Nemes wants prosecuted are the businesses that spent millions building Kentucky's medical cannabis infrastructure from scratch.

Cresco Labs operates one of the state's Tier 3 cultivation licenses — the largest category at 25,000 square feet — and completed its first harvest in April 2026. The company entered Kentucky specifically because it believed in the market's long-term potential, citing it as a "high ROIC growth initiative."

Speakeasy Dispensary operates multiple locations across the state, including Lexington, Princeton, and Ashland. Kentucky Alternative Care serves Louisville. NuEra Frankfort covers the state capital. Blue Sage Cannabis Company operates in Nicholasville. The Post Dispensary serves Beaver Dam. Newer entrants like Nature Med in Paducah and Green Releaf in Ferguson opened in recent months.

These businesses obtained licenses, built facilities, hired employees, and began serving patients — all under a regulatory framework the state itself created. Now a senior Republican legislator is asking the attorney general to prosecute them for following a governor's executive order that expands access to dying patients.

The chilling effect is the point. If operators believe they could lose their licenses for serving patients with newly added conditions, some will simply refuse to do so — leaving patients with ALS, terminal cancer, and Parkinson's without access even if the executive order stands. Nemes doesn't need the attorney general to actually prosecute anyone. The threat alone accomplishes the goal.

Coleman's Non-Answer

Attorney General Coleman's response to Nemes's request was telling in its emptiness: "As always, Representative Nemes, appreciate the input." No commitment. No pushback. No clarification of whether his office would actually pursue such prosecutions. It was the political equivalent of a shrug — which, depending on how you read it, is either reassuring or deeply concerning.

Ellis, the governor's spokesperson, called the exchange what it is: "This is the second time this week Republicans in the General Assembly have resorted to threats and intimidation against suffering or even dying Kentuckians."

The Bottom Line

Beshear's executive order would potentially extend eligibility to more than 400,000 additional Kentuckians. The conditions he added — terminal illness, ALS, Parkinson's, HIV, Huntington's, muscular dystrophy, sickle cell anemia — aren't recreational pretexts. They are among the most devastating diagnoses a human being can receive.

A University of Kentucky study linked regulated medical marijuana dispensaries to lower rates of opioid overdoses. The governor has explicitly framed cannabis as an alternative to the opioid prescriptions that have devastated Kentucky communities for decades.

And the response from Republican legislative leadership is to threaten prosecution of the businesses serving those patients.

In 2026 — with medical cannabis rescheduled to Schedule III, the DEA registering operators, and the first cannabis company trading on the NYSE — a Kentucky legislator is asking his attorney general to shut down dispensaries for helping people with ALS access a plant that the federal government now recognizes as medicine.

The program isn't being jeopardized by a governor's executive order. It's being jeopardized by lawmakers who would rather see patients suffer than cede an inch of legislative authority.

Source: Marijuana Moment

📈 Dog Walkers

$IIPR ( ▼ 1.49% ) Launches Note Offering

Innovative Industrial Properties is tapping the debt markets — and the structure tells you something about where the cannabis REIT sees opportunity.

The company's operating partnership announced plans to offer $250 million in exchangeable senior notes due 2029 through a private placement to qualified institutional buyers, with an option for initial purchasers to acquire an additional $37.5 million to cover over-allotments. The notes are senior unsecured obligations, fully guaranteed by IIP, and exchangeable for cash, common stock, or a combination at the company's option.

The capital deployment plan is notably split. Up to $50 million of net proceeds will fund repurchases of IIP common stock from certain note purchasers in privately negotiated transactions — a built-in buyback mechanism that signals management believes the stock is undervalued. The remaining proceeds are earmarked for working capital, general corporate purposes, potential debt repayment, and investments consistent with IIP's strategy of acquiring and leasing properties to state-licensed cannabis operators.

The timing is significant. IIP has been the dominant cannabis-focused REIT on the NYSE since its founding, owning properties leased to operators across the country. But the landscape around it is shifting rapidly. Trulieve just became the first plant-touching cannabis operator to list on the NYSE. Curaleaf and Verano are executing reverse splits in preparation for potential uplisting. And operators like Vireo are beginning to buy back properties they previously leased from IIP — a dynamic that could reshape the REIT's tenant relationships over time.

With Schedule III rescheduling improving operator cash flows through 280E elimination and the broader capital markets opening up to cannabis, IIP's role as the industry's landlord of last resort is evolving. The $250 million raise gives the company financial flexibility to adapt — whether that means acquiring new properties, buying back stock, or positioning for whatever the next chapter of cannabis real estate looks like.

$TSNDF ( ▲ 0.86% ) Wraps Up AGM

TerrAscend shareholders just delivered one of the most decisive votes of confidence you'll see from a cannabis company's annual meeting — and the margins tell the story.

At its June 9, 2026 annual meeting, TerrAscend shareholders re-elected all five directors with approval rates exceeding 99% across the board. Executive Chairman Jason Wild received 99.71% support, while Craig Collard led the slate at 99.74%. Kara DioGuardi came in slightly lower at 96.75% — still an overwhelming endorsement. The ratification of auditor MNP LLP passed at 99.78%, and both the stock option and share unit plan approvals cleared at approximately 99%.

In an industry where shareholder frustration has led to contentious votes, board challenges, and activist campaigns at other cannabis companies, TerrAscend's near-unanimous approval rates reflect a shareholder base that is firmly aligned with management's strategy and direction.

That alignment makes sense given what TerrAscend has delivered. The company has posted 15 consecutive quarters of positive operating cash flow and 11 straight quarters of positive free cash flow. Q1 2026 showed a return to year-over-year revenue growth with 52.8% gross margins and 26.5% adjusted EBITDA margins. The company recently filed DEA registration applications for its medical operations following Schedule III rescheduling and appointed a new CFO, Eric Jackson, to strengthen the executive team for the next phase.

Wild's continued leadership is particularly significant. As both Executive Chairman and the company's largest individual investor, his re-election with 99.71% support signals that shareholders trust the disciplined, cash-flow-focused strategy he's championed — one that has prioritized profitability and balance sheet strength over aggressive expansion.

For TerrAscend, the annual meeting was less a vote and more a ratification. When your shareholders approve everything at 99%, the message is clear: stay the course.

🗞️ The News

📺 Trade To Black

Trulieve Makes NYSE Debut: What Investors Must Know | TTB Presented by Flowhub

• Historic Trading Day: Trulieve (NYSE: TRLV) begins trading on the New York Stock Exchange, marking the first time a U.S. plant-touching cannabis operator trades on a major American exchange.

• Price Discovery: Scott Grossman of Vindico Capital breaks down what investors should expect on day one — how market makers will approach pricing and why the uplisting represents a structural shift for the entire cannabis sector.

• Liquidity Mechanics: Andrew O'Connell of Pristine Capital analyzes the practical dynamics — current $5.1M average daily dollar volume as a liquidity bottleneck, how Trulieve's fundamentals compare to the Russell 2000, and why "almost no one can fit in" today but that changes over time.

• The Bigger Picture: As a deeper investor base and improved liquidity develop, the uplisting could fundamentally reshape cannabis valuations — setting the stage for broader institutional participation across the sector as other MSOs prepare to follow.